Search research articles
Contact Us
Filters
Showing results (151-160 of 176) with videos related to
Page
of 18
Sort By:
Schizophrenia Bulletin
|
October 22, 2013
Psychosis prediction: stratification of risk estimation with information-processing and premorbid functioning variables
Dorien H Nieman, Stephan Ruhrmann, Sara Dragt, et al.
The Lancet. Psychiatry
|
January 30, 2023
Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST)
Inge Winter-van Rossum, Mark Weiser, Silvana Galderisi, et al.
Translational Psychiatry
|
December 2, 2023
Extreme deviations from the normative model reveal cortical heterogeneity and associations with negative symptom severity in first-episode psychosis from the OPTiMiSE and GAP studies
Amanda Worker, Pierre Berthert, Andrew J Lawrence, et al.
The Lancet. Psychiatry
|
August 18, 2018
Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study
René S Kahn, Inge Winter van Rossum, Stefan Leucht, et al.
Schizophrenia Bulletin
|
March 14, 2023
Association of Complement and Coagulation Pathway Proteins With Treatment Response in First-Episode Psychosis: A Longitudinal Analysis of the OPTiMiSE Clinical Trial
Subash Raj Susai, Melanie Föcking, David Mongan, et al.
The American Journal of Psychiatry
|
April 17, 2009
Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST)
Michael Davidson, Silvana Galderisi, Mark Weiser, et al.
Schizophrenia Research. Cognition
|
October 13, 2025
Premorbid functioning trajectories and the one-year course of cognitive performance in first-episode psychosis: a cluster analysis in PSYSCAN
Margot I E Slot, Hendrika H van Hell, Inge Winter-van Rossum, et al.
Schizophrenia Research
|
March 3, 2024
A naturalistic cohort study of first-episode schizophrenia spectrum disorder: A description of the early phase of illness in the PSYSCAN cohort
Margot I E Slot, Hendrika H van Hell, Inge Winter-van Rossum, et al.
The Lancet. Psychiatry
|
December 3, 2023
Relapse in clinically stable adult patients with schizophrenia or schizoaffective disorder: evidence-based criteria derived by equipercentile linking and diagnostic test accuracy meta-analysis
Spyridon Siafis, Lasse Brandt, Robert A McCutcheon, et al.
Schizophrenia (Heidelberg, Germany)
|
October 7, 2024
Multivariable prediction of functional outcome after first-episode psychosis: a crossover validation approach in EUFEST and PSYSCAN
Margot I E Slot, Maria F Urquijo Castro, Inge Winter-van Rossum, et al.
Page
of 18
Search research articles
Search
Showing results (151-160 of 176) with videos related to
Sort By:
Page
of 18
Schizophrenia Bulletin
|
October 22, 2013
Psychosis prediction: stratification of risk estimation with information-processing and premorbid functioning variables
Dorien H Nieman, Stephan Ruhrmann, Sara Dragt, et al.
The Lancet. Psychiatry
|
January 30, 2023
Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST)
Inge Winter-van Rossum, Mark Weiser, Silvana Galderisi, et al.
Translational Psychiatry
|
December 2, 2023
Extreme deviations from the normative model reveal cortical heterogeneity and associations with negative symptom severity in first-episode psychosis from the OPTiMiSE and GAP studies
Amanda Worker, Pierre Berthert, Andrew J Lawrence, et al.
The Lancet. Psychiatry
|
August 18, 2018
Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study
René S Kahn, Inge Winter van Rossum, Stefan Leucht, et al.
Schizophrenia Bulletin
|
March 14, 2023
Association of Complement and Coagulation Pathway Proteins With Treatment Response in First-Episode Psychosis: A Longitudinal Analysis of the OPTiMiSE Clinical Trial
Subash Raj Susai, Melanie Föcking, David Mongan, et al.
The American Journal of Psychiatry
|
April 17, 2009
Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST)
Michael Davidson, Silvana Galderisi, Mark Weiser, et al.
Schizophrenia Research. Cognition
|
October 13, 2025
Premorbid functioning trajectories and the one-year course of cognitive performance in first-episode psychosis: a cluster analysis in PSYSCAN
Margot I E Slot, Hendrika H van Hell, Inge Winter-van Rossum, et al.
Schizophrenia Research
|
March 3, 2024
A naturalistic cohort study of first-episode schizophrenia spectrum disorder: A description of the early phase of illness in the PSYSCAN cohort
Margot I E Slot, Hendrika H van Hell, Inge Winter-van Rossum, et al.
The Lancet. Psychiatry
|
December 3, 2023
Relapse in clinically stable adult patients with schizophrenia or schizoaffective disorder: evidence-based criteria derived by equipercentile linking and diagnostic test accuracy meta-analysis
Spyridon Siafis, Lasse Brandt, Robert A McCutcheon, et al.
Schizophrenia (Heidelberg, Germany)
|
October 7, 2024
Multivariable prediction of functional outcome after first-episode psychosis: a crossover validation approach in EUFEST and PSYSCAN
Margot I E Slot, Maria F Urquijo Castro, Inge Winter-van Rossum, et al.
Page
of 18